ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.532,68
-1,33%
S&P 500
5.942,47
1,26%
US Dollar vs BRL
6,1822
0,00%
Bitcoin
98.275,06
0,07%
Brent Oil
76,495
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Foghorn Therapeutics Inc (FHTX)

  7. Foghorn Therapeutics Inc (FHTX) Notícias

FHTX

Foghorn Therapeutics (FHTX)

Foghorn Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:FHTX
DataHoraFonteTítuloCódigoCompanhia
30/12/202409:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FHTXFoghorn Therapeutics Inc
16/12/202409:00GlobeNewswire Inc.Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic PrioritiesNASDAQ:FHTXFoghorn Therapeutics Inc
12/11/202409:54GlobeNewswire Inc.Foghorn Therapeutics to Participate in Three Upcoming Investor ConferencesNASDAQ:FHTXFoghorn Therapeutics Inc
04/11/202418:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FHTXFoghorn Therapeutics Inc
23/10/202409:00PR Newswire (US)Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering IntelligenceNASDAQ:FHTXFoghorn Therapeutics Inc
10/10/202408:00GlobeNewswire Inc.Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid TumorsNASDAQ:FHTXFoghorn Therapeutics Inc
08/10/202418:44Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FHTXFoghorn Therapeutics Inc
03/10/202409:00PR Newswire (US)Invaio Sciences Appoints André Andonian as Chairman of the Board of DirectorsNASDAQ:FHTXFoghorn Therapeutics Inc
01/10/202408:00GlobeNewswire Inc.Foghorn Therapeutics to Participate in the BMO Oncology SummitNASDAQ:FHTXFoghorn Therapeutics Inc
24/09/202417:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FHTXFoghorn Therapeutics Inc
16/09/202417:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FHTXFoghorn Therapeutics Inc
04/09/202417:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:FHTXFoghorn Therapeutics Inc
03/09/202408:00GlobeNewswire Inc.Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business OfficerNASDAQ:FHTXFoghorn Therapeutics Inc
28/08/202408:00GlobeNewswire Inc.Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberNASDAQ:FHTXFoghorn Therapeutics Inc
08/08/202409:44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FHTXFoghorn Therapeutics Inc
06/08/202407:30PR Newswire (US)Flagship Pioneering Announces Appointment of Raj Panjabi as Senior PartnerNASDAQ:FHTXFoghorn Therapeutics Inc
28/05/202408:00GlobeNewswire Inc.Foghorn Therapeutics to Participate in Upcoming Investor Conferences in JuneNASDAQ:FHTXFoghorn Therapeutics Inc
22/05/202419:21GlobeNewswire Inc.Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance PipelineNASDAQ:FHTXFoghorn Therapeutics Inc
06/05/202408:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FHTXFoghorn Therapeutics Inc
07/03/202409:09Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FHTXFoghorn Therapeutics Inc
27/11/202321:01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:FHTXFoghorn Therapeutics Inc
21/11/202308:00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:FHTXFoghorn Therapeutics Inc
01/11/202311:30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:FHTXFoghorn Therapeutics Inc
11/09/202307:30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:FHTXFoghorn Therapeutics Inc
05/09/202309:00GlobeNewswire Inc.Foghorn Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:FHTXFoghorn Therapeutics Inc
31/08/202308:00GlobeNewswire Inc.Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AMLNASDAQ:FHTXFoghorn Therapeutics Inc
29/08/202310:00PR Newswire (US)Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyNASDAQ:FHTXFoghorn Therapeutics Inc
08/08/202308:00GlobeNewswire Inc.Foghorn Therapeutics Announces Chief Medical Officer SuccessionNASDAQ:FHTXFoghorn Therapeutics Inc
04/08/202308:00GlobeNewswire Inc.Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate UpdateNASDAQ:FHTXFoghorn Therapeutics Inc
28/06/202308:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FHTXFoghorn Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:FHTX

Seu Histórico Recente

BOV
PRIO3
PETRORIO ON
BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados